🇺🇸 FDA
Pipeline program

Psilocybin

253490

Phase 2 small_molecule completed

Quick answer

Psilocybin for Treatment Resistant Depression is a Phase 2 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COGNITION THERAPEUTICS INC
Indication
Treatment Resistant Depression
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials